Ablynx has started an IND-enabling toxicology study with a bi-specific Nanobody as part of its immuno-oncology collaboration with Merck. This milestone triggers a €2.5 million payment to Ablynx. The Nanobody is a bi-specific molecule that selectively binds to two different immune modulators, believed to be key targets for the development of potent immunotherapies. Upon successful completion of the IND package, this bi-specific Nanobody could be the first candidate to enter clinical studies a...